CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors as second-line treatments for hormone receptor-positive, HER2-negative advanced breast cancer: a network meta-analysis. - Ji, Danyang; Luo, Yang; Wang, Jiayu; Chen, Shanshan; Lan, Bo; Ma, Fei; Xu, Binghe; Fan, Ying (BMC Cancer, 2023)